Literature DB >> 24634681

Respiratory syncytial virus and palivizumab: Where are we in 2014?

Joan Robinson.   

Abstract

Entities:  

Year:  2014        PMID： 24634681      PMCID： PMC3950994          DOI： 10.1155/2014/158919

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN： 1712-9532            Impact factor:   2.471


× No keyword cloud information.
  18 in total

1.  RSV immunoprophylaxis: does the benefit justify the cost?

Authors:  H Cody Meissner; David W Kimberlin
Journal:  Pediatrics       Date:  2013-10-14       Impact factor: 7.124

2.  Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation.

Authors:  John S Sampalis; Joanne Langley; Xavier Carbonell-Estrany; Bosco Paes; Karel O'Brien; Upton Allen; Ian Mitchell; José Figueras Aloy; Carmen Pedraz; Andrea F Michaliszyn
Journal:  Med Decis Making       Date:  2008-06-12       Impact factor: 2.583

3.  Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.

Authors:  Almut G Winterstein; Caitlin A Knox; Paul Kubilis; Christian Hampp
Journal:  JAMA Pediatr       Date:  2013-12       Impact factor: 16.193

4.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

Authors:  S Johnson; C Oliver; G A Prince; V G Hemming; D S Pfarr; S C Wang; M Dormitzer; J O'Grady; S Koenig; J K Tamura; R Woods; G Bansal; D Couchenour; E Tsao; W C Hall; J F Young
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

5.  Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays.

Authors:  Damon J Deming; Nita Patel; Michael P McCarthy; Lalji Mishra; Alan M Shapiro; JoAnn A Suzich
Journal:  Pediatr Infect Dis J       Date:  2013-10       Impact factor: 2.129

6.  Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.

Authors:  Gabriel J Robbie; Liang Zhao; John Mondick; Genevieve Losonsky; Lorin K Roskos
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

7.  Preventing respiratory syncytial virus infections.

Authors:  Jl Robinson
Journal:  Paediatr Child Health       Date:  2011-10       Impact factor: 2.253

8.  Seasonal respiratory syncytial virus prophylaxis based on predetermined dates versus regional surveillance data.

Authors:  Bosco A Paes; Carole Craig; Wendy Pigott; Andrew Latchman
Journal:  Pediatr Infect Dis J       Date:  2013-09       Impact factor: 2.129

9.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

10.  Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.

Authors:  K N Subramanian; L E Weisman; T Rhodes; R Ariagno; P J Sánchez; J Steichen; L B Givner; T L Jennings; F H Top; D Carlin; E Connor
Journal:  Pediatr Infect Dis J       Date:  1998-02       Impact factor: 2.129
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.